# Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients

Source: https://onco.cc/trials/nct02802540/  
OnCo record `nct02802540` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2/3 trial of Nabilone in Non-small-cell lung cancer, run by Instituto Nacional de Cancerologia de Mexico, with a status the registry has not verified recently.

## Summary

Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients is a phase 2/3 interventional study registered as NCT02802540 by Instituto Nacional de Cancerologia de Mexico, with 78 participants planned, started 2014-12 and due to reach its primary completion in 2017-07. Interventions recorded: Nabilone, Placebo. Conditions recorded: Non-Small Cell Lung Cancer, Anorexia, Cachexia, Weight Lose.

Linked to the drug Nabilone because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT02802540
- Phase: 2/3
- Setting: Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Patients With Anorexia Associated With Advanced Lung Cancer: Randomized Double Blind Clinical Trial
- Sponsor: Instituto Nacional de Cancerologia de Mexico
- Enrolled: 78

## Sources

- ClinicalTrials.gov NCT02802540: https://clinicaltrials.gov/study/NCT02802540

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [Nabilone](https://onco.cc/drugs/nabilone/)

---
JSON: https://onco.cc/api/v1/entities/nct02802540.json